Madrigal Pharmaceuticals, Inc. Forecast, price target & analysts
Madrigal Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
Madrigal Pharmaceuticals, Inc. Classifications & Recommendation
Madrigal Pharmaceuticals, Inc. Price Target
| Target Price | $666.06 |
| Price | $516.56 |
| Potential |
28.94%
register free of charge
|
| Number of Estimates | 19 |
|
19 Analysts have issued a price target Madrigal Pharmaceuticals, Inc. 2027 .
The average Madrigal Pharmaceuticals, Inc. target price is $666.06.
This is
28.94%
register free of charge
$1,010.10
95.54%
register free of charge
$548.43
6.17%
register free of charge
|
|
| A rating was issued by 24 analysts: 22 Analysts recommend Madrigal Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Madrigal Pharmaceuticals, Inc. stock has an average upside potential 2027 of
28.94%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 0.96 | 1.56 |
| 432.06% | 62.67% | |
| EBITDA Margin | -31.16% | -12.06% |
| 88.70% | 61.29% | |
| Net Margin | -30.08% | -9.58% |
| 88.37% | 68.15% |
20 Analysts have issued a sales forecast Madrigal Pharmaceuticals, Inc. 2026 . The average Madrigal Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Madrigal Pharmaceuticals, Inc. EBITDA forecast 2026. The average Madrigal Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Madrigal Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average Madrigal Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -12.85 | -6.47 |
| 41.32% | 49.65% | |
| P/E | negative | |
| EV/Sales | 7.34 |
19 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast for earnings per share. The average Madrigal Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Madrigal Pharmaceuticals, Inc....
Current Madrigal Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| Wolfe Research |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jul 29 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Jul 27 2026 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Jun 11 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | May 13 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citigroup:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 03 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jul 29 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Jul 27 2026 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Jun 11 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
May 13 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
